Chonluten Research GuideGlu-Asp-Gly (EDG) · not Bronchogen · not FDA-approved
Chonluten is a synthetic tripeptide printed in opened Khavinson-group papers as Glu-Asp-Gly (EDG), positioned as a short peptide bioregulator associated with respiratory-tissue / bronchial-epithelium research. English-language independently replicated evidence is sparse. It is not Bronchogen, not Epitalon, and not an FDA-approved drug on any opened registry. Research use only. Not medical advice. Not for human use.
Glu-Asp-Gly
Sparse evidence
Not Bronchogen
Not FDA-approved
Educational information only. This page describes a short peptide bioregulator sold as a laboratory research material. It is not medical advice. Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application. Sequence Glu-Asp-Gly / EDG is taken from opened papers, not from the SRP product page. No human dosing, reconstitution, or administration protocol appears on this page.
Sequence and chemical identity
SRP product and index pages do not print a sequence, CAS, UNII, molecular formula, or a public COA. The sequence below is taken only from opened primary papers that print the trade name Chonluten next to the three-letter sequence. The CAS / formula / CID row is the opened PubChem record for glutamyl-aspartyl-glycine (Glu-Asp-Gly). PubChem does not list the trade name Chonluten as a synonym.
One-sentence identity: Chonluten is a synthetic tripeptide printed in opened Khavinson-group papers as Glu-Asp-Gly (EDG), positioned as a short peptide bioregulator associated with respiratory-tissue / bronchial-epithelium research. English-language independently replicated evidence is limited. It is not Bronchogen, not Epitalon, and not an FDA-approved drug on any opened registry.
| Identifier | Value on opened page | Source opened |
|---|---|---|
| Trade name on SRP | Chonluten 20 mg Research Peptide Vial | SRP product page |
| SRP listed strength / format | 20 mg; one 20 mg research vial; verify sequence, salt form, and assay | SRP product page |
| SRP store categories | Peptide Bioregulators; Research Peptides; Respiratory Research | SRP product page (store taxonomy, not a clinical indication) |
| SRP index category / evidence tag | Longevity listing Chonluten 20 mg; evidence tag Sparse/limited evidence | SRP compound-research-guides index |
| Sequence printed with the name Chonluten | Glu-Asp-Gly (one-letter EDG); tripeptide Glu-Asp-Gly, from respiratory lung | Avolio et al. 2022, PMID 35408963, Methods 4.1 |
| Sequence printed as EDG = Chonluten | EDG tripeptide (Chonluten) | Khavinson et al. 2020, PMID 32987757, full text |
| Sequence printed as Chonluten (EDG) | Table 2: Chonluten (EDG) | Khavinson et al. 2022, PMID 35887081, Table 2 |
| PubChem CID (Glu-Asp-Gly structure) | 194641. Title: Glutamyl-aspartyl-glycine. Description: Glu-Asp-Gly is a tripeptide. | PubChem PUG REST / PUG View, opened 16 August 2026 |
| PubChem name lookup chonluten / honluten | PUGREST.NotFound — no CID under those trade names | PubChem PUG REST |
| CAS on the Glu-Asp-Gly CID | 75007-24-8 | PubChem CID 194641 (CAS heading + RN xref) |
| Molecular formula / MW | C11H17N3O8; 319.27 | PubChem CID 194641 |
| Exact / monoisotopic mass | 319.10156451 | PubChem PUG property |
| InChIKey | DSPQRJXOIXHOHK-WDSKDSINSA-N | PubChem CID 194641 |
| IUPAC name (PubChem computed) | (4S)-4-amino-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid | PubChem CID 194641 |
| PubChem / MeSH synonyms on CID 194641 | Glu-Asp-Gly; H-Glu-Asp-Gly-OH; T-34 tripeptide; L-Glutamyl-L-aspartyl-glycine | PubChem PUG View (MeSH + depositor synonyms) |
| ChEBI (PubChem xref only) | CHEBI:162780. The ChEBI HTML/REST pages returned error/empty and were not used beyond the PubChem pointer. | PubChem xrefs / description |
| Other PubChem xrefs | DTXSID80996513; SCHEMBL3909775 | PubChem xrefs |
| UNII | Not found on opened PubChem, NCATS, or FDA UNII pages | PubChem PUG View (no UNII heading); NCATS search chonluten = 0; precision.fda.gov UNII API 404 |
| NCATS Inxight | No substance record named chonluten | NCATS API + HTML search, opened 16 August 2026 |
| IUPHAR / GtoPdb | No ligand for chonluten or Glu-Asp-Gly | IUPHAR services API |
| ClinicalTrials.gov | 0 studies for chonluten, honluten, or Glu-Asp-Gly. No trial registration number is available to list. | CT.gov API v2, opened 16 August 2026 |
| openFDA Drugs@FDA / labels | No matches for chonluten | openFDA API, opened 16 August 2026 |
| INN / USAN | None on any opened registry | — |
What this is chemically, from opened pages. Three independent opened Khavinson-group papers print Chonluten as the unmodified tripeptide Glu-Asp-Gly (EDG). Avolio et al. 2022 additionally state that some of the peptides, including Chonluten, were synthetized on the basis of the information of their natural counterparts, and that Chonluten is from respiratory lung / derived from bronchial epithelial cells. PubChem CID 194641 is the matching L-Glu–L-Asp–Gly structure (CAS 75007-24-8; synonym T-34 tripeptide). That CID does not print the marketplace name Chonluten.
What this is not, chemically.
- Not Bronchogen. Opened pages print Bronchogen as a tetrapeptide. The printed one-letter order is not even internally consistent (ADEL vs AEDL). See the next section.
- Not Epitalon (Ala-Glu-Asp-Gly / AEDG), Livagen (KEDA on the opened transport table), Ovagen (EDL on that table), Vesugen (KED on that table), Pinealon (EDR), Vilon (Lys-Glu), or Thymogen (Glu-Trp). Those sequences are printed on opened Avolio 2022 Methods and/or Khavinson 2022 Table 2.
- Not a defined-receptor ligand on IUPHAR.
- Not shown on any opened page to be compositionally identical to an SRP 20 mg lyophilized research vial. SRP itself tells the buyer to verify sequence, salt form, and assay.
Not printed on SRP pages and therefore not claimed as SRP-verified: sequence, CAS, UNII, formula, T-34 code, or purity numbers. The product page does not print a public COA.
Honluten. Europe PMC REST returned 0 records for honluten. No opened primary paper printed that spelling. Vendor/blog pages that treat Honluten as a synonym were not used as identity sources.
How it relates to — and is not — other Khavinson bioregulators, or Bronchogen
Chonluten (this page) is the tripeptide Glu-Asp-Gly (EDG) on the opened Avolio 2022, Khavinson 2020, and Khavinson 2022 pages. It is one name inside the Khavinson / cytomedin-style short-peptide bioregulator catalog. That catalog is a research-network taxonomy, not a receptor-class assignment.
Bronchogen is a different molecule. Do not cite Bronchogen papers as Chonluten evidence. Opened pages print Bronchogen as a tetrapeptide. The printed one-letter order is not even internally consistent: some papers print ADEL (Ala-Asp-Glu-Leu) and others print AEDL (Ala-Glu-Asp-Leu). Those are not the same four residues in the same order. This page records both printings and does not collapse them.
| Opened page | What it printed for bronchogen / the lung tetrapeptide | Why it is not Chonluten |
|---|---|---|
| Khavinson et al. 2020 PMID 32987757 |
AEDL tetrapeptide (Bronchogen) vs EDG tripeptide (Chonluten) | Explicitly a different sequence and a different trade name. |
| Khavinson et al. 2022, Table 2 PMID 35887081 |
Bronchogen (AEDL), ICM-score −17.26, labeled Bronchoprotector; Chonluten (EDG), ICM-score −30.30, labeled Gastroprotector / Stress protector | Same table, two rows, two sequences. |
| Khavinson et al. 2014, Lung PMID 25015171 — NOT Chonluten efficacy |
Tetrapeptide Ala-Asp-Glu-Leu (ADEL) in human embryonic bronchial-epithelium cultures; gene/protein panel (Ki67, Mcl-1, p53, NKX2-1, MUC4, MUC5AC, SFTPA1, etc.) | Sequence printed is ADEL, not EDG. Abstract never names Chonluten. |
| Monaselidze et al. 2011 PMID 21240358 — NOT Chonluten efficacy |
peptide bronchogen (Ala-Asp-Glu-Leu) as a DNA-stabilizing ligand | ADEL tetrapeptide, not EDG. |
| Khavinson et al. 2012 PMID 22808515 — NOT Chonluten efficacy |
bronchogen (Ala-Glu-Asp-Leu) stimulated CXCL12 / Hoxa3 in aging bronchial-cell cultures | AEDL tetrapeptide, not EDG. |
| Kuzubova et al. 2015 PMID 26468022 — NOT Chonluten efficacy |
tetrapeptide Bronchogen for 1 month in a rat NO2 COPD model | Tetrapeptide; not named Chonluten or EDG. |
Opened-source inconsistency on Bronchogen
PMID 25015171 and PMID 21240358 print Ala-Asp-Glu-Leu (ADEL). PMID 22808515 and PMID 32987757 / PMID 35887081 print Ala-Glu-Asp-Leu (AEDL). Those are not the same four residues in the same order. This page records both printings and does not collapse them. Do not merge Bronchogen into Chonluten.
Epitalon is AEDG, not EDG
Epitalon (AEDG) is printed in Avolio 2022 Methods as Ala-Glu-Asp-Gly, from pineal gland. Four residues, different N-terminus. Do not treat Epitalon telomerase / melatonin papers as Chonluten evidence.
Livagen, Ovagen, Vesugen
These appear on the opened 2022 transport table as KEDA, EDL, and KED respectively, with different tissue labels (hepato-/nephro-protector; vasoprotector). They are catalog siblings, not synonyms of Chonluten.
T-34 is not a confirmed Chonluten trial
PubChem lists T-34 tripeptide as a synonym of Glu-Asp-Gly (CID 194641). Khavinson et al. 2012 (PMID 22803148) is an opened abstract-only paper about geroprotective peptide T-34 in a gastric-ulcer setting. That opened abstract does not print the name Chonluten, the letters EDG, or the sequence Glu-Asp-Gly. The 2020 COVID review cites this paper when it attributes c-Fos / HSP70 / SOD / COX-2 / TNF-α regulation to EDG. Because the 2012 full text was subscription-walled and the opened abstract does not print those gene names or the Chonluten trade name, this page does not treat PMID 22803148 as a confirmed Chonluten primary experiment. Label: NOT Chonluten efficacy.
Proposed mechanism (label the evidence layer)
Opened pages support a working model from one research network, not a locked receptor identity. None of this is a treatment claim, and none of it identifies which salt or assay is in an SRP vial. Observed means a measurement in an opened paper that names Chonluten. Proposed means docking or review-level language. Class / review means related-family or review text. Not shown means the opened papers did not establish it.
Tissue-associated short peptide, not a named GPCR ligand
Avolio et al. 2022 call Chonluten a synthetic bronchial bio-regulator whose principal biological targets are the respiratory system, and they state that Khavinson peptides were initially isolated from animal tissues and found to be organ specific. IUPHAR returned no ligand. No opened paper printed a single defined cell-surface receptor for EDG. (PMID 35408963.)
The only opened primary experiment that names and tests Chonluten
Avolio et al. 2022 incubated THP-1 cells with 100 ng/mL of each peptide overnight, ± 100 ng/mL LPS. Findings specific to Chonluten (P5) on that opened full text: a moderate but consistent apoptotic profile on FACS, doubling the value in relation to other peptides (Supplementary Data; the main text does not print a numeric apoptotic percentage); a slight release of TNF from otherwise unstimulated monocytes, which the authors interpret as a possible TNF-tolerance / anergy signal — not as a proinflammatory disease finding; together with Epitalon and Vilon, Chonluten increased STAT1 phosphorylation in PMA-differentiated THP-1 macrophages, functioning possibly via a receptor-independent mechanism, with no effect on IFN-α production. (PMID 35408963.)
ERK, LPS cytokines, HUVEC adhesion
Shared with the other four peptides, not unique to Chonluten: increased ERK1/2 phosphorylation (all except Vilon); reduced LPS-stimulated TNF-α, IL-6, and (to varying degrees) IL-17; reduced adhesion of peptide-pretreated THP-1 cells to LPS-activated HUVECs. This is a human leukemia monocytic cell line. It is not bronchial epithelium, not an animal lung-injury model, and not a human trial. (PMID 35408963.)
Transporter docking is a model, not uptake data
Khavinson et al. 2022 (review + ICM docking) list Chonluten (EDG) among ultrashort peptides with a LAT1 docking ICM-score of −30.30, among the more favorable scores in that table (Vesilut/ED −34.32; Pinealon/EDR −30.29; Bronchogen/AEDL only −17.26). The paper’s claim is that di- and tripeptides can be LAT1/POT substrates depending on structure. It does not measure Chonluten flux in a cell, and the same table labels EDG a gastroprotector / stress protector, not a bronchoprotector. (PMID 35887081.)
Gene-regulation language is review-level
The 2020 COVID review states that EDG’s stress-protective effect is associated with its ability to regulate the expression of the c-Fos gene, the heat shock protein gene HSP70, the genes encoding the enzymes of the antioxidant system, SOD, COX-2 and the tumor necrosis factor gene TNF-α, citing PMID 22803148. That citation’s opened abstract is a gastric-ulcer T-34 paper and does not print those gene names. The opened 2014 Lung gene-expression paper (PMID 25015171) is ADEL, not EDG. Do not transfer the ADEL bronchial gene panel (NKX2-1, FOXA1/2, MUC4, MUC5AC, SFTPA1) onto Chonluten. (PMID 32987757.) 2020 review oral COPD / COVID language = unverified review claims.
DNA / histone / nuclear-entry story
The 2021 systematic review (PMID 34834147) discusses 2–7 residue peptides penetrating nuclei and contacting DNA/histones. Its opened full text does not mention Chonluten or Glu-Asp-Gly. It is background for the bioregulator hypothesis, not a Chonluten mechanism paper. Label: NOT Chonluten efficacy.
Where the literature actually sits
Human numbers below, where a review mentions them, are unverified review assertions. They are not instructions for using SRP research vials, and they are not claims that research-grade material works in people.
English-language independently replicated evidence is limited / sparse. Almost every opened record is from the Saint Petersburg Institute of Bioregulation and Gerontology network or a collaboration that includes Khavinson as a co-author. Europe PMC search for chonluten returned 3 hits. Only one opened primary experiment (Avolio 2022, THP-1 cells) names and tests Chonluten. No trial registration. No opened human RCT.
Avolio 2022 THP-1 — one cell paper
Avolio et al., Int J Mol Sci 2022. PMID 35408963. DOI 10.3390/ijms23073607. PMC8999041. Human THP-1 monocytes ± PMA to macrophages; 100 ng/mL peptide overnight ± 100 ng/mL LPS; HUVEC adhesion. Methods print Chonluten = Glu-Asp-Gly. This is the only opened primary experiment that names and tests Chonluten. Not lung tissue. Not an animal model. Not a human trial.
Two reviews — not new trials
Khavinson et al. 2020 COVID review (PMID 32987757) prints EDG tripeptide (Chonluten) and asserts oral EDG use in bronchopulmonary pathology. Those oral COPD / COVID sentences are unverified review claims. Khavinson et al. 2022 transport review + docking (PMID 35887081) prints Chonluten (EDG) with LAT1 ICM-score −30.30. Neither paper is a new trial.
Bronchogen / ADEL / T-34 / class review
Logged so they are not silently reused. PMID 25015171 ADEL Lung gene panel. PMID 21240358 Bronchogen ADEL DNA. PMID 22808515 Bronchogen AEDL. PMID 26468022 rat Bronchogen COPD. PMID 30199201 tetrapeptide bronchogen COPD model. PMID 22803148 T-34 gastric abstract only. PMID 34834147 class review, 0 hits for Chonluten. All labeled NOT Chonluten efficacy.
NONE opened
ClinicalTrials.gov API v2 returned 0 studies for chonluten, honluten, or Glu-Asp-Gly. No trial registration number is available to list. Do not invent one. The 2020 review’s sentences about COPD, chronic bronchitis, hypoxia, and standard therapy are not backed by an opened protocol, results table, or PubMed-indexed RCT that this pass could retrieve under those names.
SRP 20 mg page prints no sequence
Opened SRP page: Chonluten 20 mg Research Peptide Vial; $45.00; categories Peptide Bioregulators / Respiratory Research; verify sequence, salt form, and assay. Sequence, CAS, UNII, molecular formula, and a public COA were not printed. Index tag: Sparse/limited evidence. Product page.
False equivalences
Chonluten = Bronchogen is false. Chonluten = Epitalon is false. Honluten is the same thing is not printed on any opened primary paper. FDA approved / treats COPD / asthma / COVID is contradicted by openFDA empty results, ClinicalTrials.gov zero studies, and the fact that the COVID paper is a review of prospects. Do not use those claims.
Primary experiment that names and tests Chonluten
Read the what it did not show column. Published study designs are historical facts from those papers. They are not a protocol. Evidence is sparse: this is the only opened primary cell paper.
| Study | Model | What it showed | What it did not show |
|---|---|---|---|
| Avolio et al., Int J Mol Sci 2022 PMID 35408963. DOI 10.3390/ijms23073607. PMC8999041. |
Human THP-1 monocytes ± PMA → macrophages; 100 ng/mL peptide overnight ± 100 ng/mL LPS; HUVEC adhesion assay (peptides 8 h; HUVEC LPS 5 µg/mL × 12 h). Five Khavinson peptides side by side. Khavinson, Mironova, Trofimova among authors. | Methods print Chonluten = Glu-Asp-Gly. Chonluten-specific: modest apoptosis increase; slight unstimulated TNF; STAT1 phosphorylation with Epitalon/Vilon. Shared: ERK1/2 (except Vilon); lower LPS-driven TNF-α / IL-6; less THP-1 adhesion to activated endothelium. Authors: peptides cooperate as natural inducers of TNF tolerance. | Lung tissue. An animal model. A human trial. A receptor. PK. That 100 ng/mL maps to any research-vial amount. Independence from the Khavinson network. |
Avolio, Martinotti, Khavinson, et al., 2022 — Int J Mol Sci
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Methods 4.1 print P5 as Chonluten (tripeptide Glu-Asp-Gly, from respiratory lung). Chonluten-specific findings on the opened full text: moderate but consistent apoptotic profile on FACS; slight unstimulated TNF; STAT1 phosphorylation with Epitalon and Vilon, possibly via a receptor-independent mechanism, no effect on IFN-α. Shared findings: ERK1/2 (except Vilon); reduced LPS-stimulated TNF-α, IL-6, and (to varying degrees) IL-17; reduced THP-1 adhesion to LPS-activated HUVECs. This is a human leukemia monocytic cell line, not bronchial epithelium, not an animal lung-injury model, and not a human trial. PMID 35408963. DOI 10.3390/ijms23073607. PMC8999041.
Reviews that name Chonluten / EDG (not new trials)
These papers name Chonluten or EDG. They are not new trials. The 2020 review’s oral COPD / COVID sentences are unverified review claims.
| Study | What the opened text actually said | What it did not show |
|---|---|---|
| Khavinson et al., Molecules 2020. Review. PMID 32987757. DOI 10.3390/molecules25194389. PMC7583759. |
Prints EDG tripeptide (Chonluten) and AEDL tetrapeptide (Bronchogen). Asserts that oral EDG is effective for the treatment of bronchopulmonary pathology (chronic obstructive pulmonary disease, chronic bronchitis with an asthmatic component); that oral EDG increased a physical performance index and normalization of the organism functional state when exposed to low oxygen partial pressure; and that EDG enhanced the effectiveness of standard therapy in patients with chronic bronchitis with an asthmatic component. Attributes c-Fos / HSP70 / SOD / COX-2 / TNF-α regulation to EDG, citing PMID 22803148. Proposes EDG/AEDL as possible COVID-19 adjuncts. | No methods, n, endpoints, or trial registration. The cited gene-regulation paper’s opened abstract is a gastric T-34 study, not a Chonluten RCT. This is a narrative review from the same institute. It is not an opened human trial. Oral COPD / COVID = unverified review claims. |
| Khavinson et al., Int J Mol Sci 2022. Review + docking. PMID 35887081. DOI 10.3390/ijms23147733. PMC9323678. |
Table 2 prints Chonluten (EDG), ICM-score −30.30, Gastroprotector / Stress protector. Authors conclude di-/tripeptides may use POT/LAT carriers. | Measured cellular uptake of Chonluten. A lung efficacy study. A human trial. LAT1 docking only. |
Khavinson, Linkova, Dyatlova, Kuznik, Umnov, 2020 — Molecules
Peptides: Prospects for Use in the Treatment of COVID-19. Prints EDG tripeptide (Chonluten) versus AEDL tetrapeptide (Bronchogen). Oral COPD / chronic bronchitis / hypoxia / standard-therapy sentences are author language from this narrative review. They are not an opened RCT, not a protocol, and not a results table. Gene-list claim cites PMID 22803148 (T-34 gastric abstract; not confirmed as a Chonluten primary experiment). PMID 32987757. DOI 10.3390/molecules25194389. PMC7583759.
Khavinson, Linkova, Kozhevnikova, Dyatlova, Petukhov, 2022 — Int J Mol Sci
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Table 2 prints Chonluten (EDG), ICM-score −30.30, Gastroprotector / Stress protector; Bronchogen (AEDL) −17.26 Bronchoprotector. Does not measure Chonluten flux in a cell. PMID 35887081. DOI 10.3390/ijms23147733. PMC9323678.
Opened papers that are NOT Chonluten evidence
Logged so they are not silently reused. Each row is labeled NOT Chonluten efficacy. Do not cite these as Chonluten proof.
| Study | Why it is out of scope for Chonluten efficacy |
|---|---|
| Khavinson et al., Lung 2014 PMID 25015171. DOI 10.1007/s00408-014-9620-7. NOT Chonluten efficacy |
Tests ADEL, not EDG. Bronchial-epithelium gene/protein data belong to that tetrapeptide. Do not transfer NKX2-1, FOXA1/2, MUC4, MUC5AC, SFTPA1 onto Chonluten. |
| Monaselidze et al., Bull Exp Biol Med 2011 PMID 21240358. DOI 10.1007/s10517-011-1146-x. NOT Chonluten efficacy |
Bronchogen printed as Ala-Asp-Glu-Leu. DNA melting, not Chonluten. |
| Khavinson et al., Bull Exp Biol Med 2012 PMID 22808515. DOI 10.1007/s10517-012-1664-1. NOT Chonluten efficacy |
Bronchogen printed as Ala-Glu-Asp-Leu in aging bronchial cultures. |
| Kuzubova et al., Bull Exp Biol Med 2015 PMID 26468022. DOI 10.1007/s10517-015-3047-x. NOT Chonluten efficacy |
Rat NO2 COPD model of tetrapeptide Bronchogen. |
| Titova et al. 2017 PMID 30199201. (Russian title; no DOI on the opened Europe PMC record.) NOT Chonluten efficacy |
Abstract: tetrapeptide bronchogen in a COPD model. Logged; not used as Chonluten evidence. |
| Khavinson et al., Bull Exp Biol Med 2012. Abstract only. PMID 22803148. DOI 10.1007/s10517-012-1590-2. NOT Chonluten efficacy |
Peptide T-34 / gastric ulcer. Opened abstract does not print Chonluten or Glu-Asp-Gly. Full text not opened (subscription). |
| Khavinson et al., Molecules 2021 PMID 34834147. DOI 10.3390/molecules26227053. PMC8619776. NOT Chonluten efficacy |
Systematic review of short-peptide gene regulation. Opened full text: 0 hits for Chonluten / Glu-Asp-Gly. Class background only. |
Human trials: NONE
None opened. ClinicalTrials.gov API v2 returned 0 studies for chonluten, honluten, or Glu-Asp-Gly. No trial registration number is available to list. Do not invent one.
The 2020 review’s sentences about COPD, chronic bronchitis, hypoxia, and standard therapy are not backed by an opened protocol, results table, or PubMed-indexed RCT that this pass could retrieve under those names. Those sentences remain unverified review claims.
This page does not provide reconstitution, administration, or dosing instructions. Historical review language about oral EDG is not a protocol for an SRP research vial.
Regulatory status (opened pages only)
Bottom line from opened sources: Chonluten is a research-marketplace / Khavinson-catalog name for a tripeptide. It is not FDA-approved as a US drug on any opened FDA or NCATS page. An SRP research vial is not a licensed medicine. Research use only. Not medical advice. Not for human use.
| Claim | What an opened page actually said | What we did not open / confirm |
|---|---|---|
| US FDA marketing approval | openFDA Drugs@FDA and label APIs: No matches found for chonluten. NCATS Inxight HTML/API: no substance named chonluten. IUPHAR: no ligand. | A Drugs@FDA NDA/BLA page (none found). Do not invent an NDA, ANDA, or BLA number. |
| UNII / GSRS | PubChem CID 194641 printed no UNII. FDA UNII search API path returned 404. NCATS name search empty. | A UNII for Glu-Asp-Gly. Absence of a found UNII is not proof that SRS will never assign one. |
| INN / USAN | None on opened WHO/NCATS/IUPHAR pages. | A WHO INN list entry (not found, not opened). |
| Marketed dietary-supplement use in Russia / CIS | Not independently confirmed on an opened regulator page. The 2020 review discusses oral EDG as if it were used clinically; that is author language, not an FDA/EMA authorization. | A country-by-country marketing-authorization table. |
What is NOT established
The following are not established on opened pages. Keep this list visible. Sparse evidence is not mixed evidence.
Any human efficacy, dose, route, or treatment effect
No opened RCT, no trial registration, no opened primary clinical paper that names Chonluten. Review sentences about COPD, asthmatic-component bronchitis, hypoxia, and standard therapy remain unverified.
FDA (or opened EMA) approval
Not FDA-approved for any indication on opened FDA, NCATS, or openFDA pages as of 16 August 2026.
English-language independent replication
The THP-1 findings, or any lung-specific EDG experiment, have not been independently replicated outside the Khavinson network in opened English-language papers.
A receptor, human PK, oral bioavailability, half-life, or tissue distribution
No opened paper identified a defined cell-surface receptor for Chonluten / EDG. No opened pharmacokinetics program.
That the 2014 Lung ADEL gene panel, or the 2015 rat Bronchogen COPD model, describes Chonluten
Those are different sequences on the opened pages (ADEL / tetrapeptide Bronchogen vs EDG).
That PubChem CID 194641 is an official Chonluten registration
The CID is Glu-Asp-Gly / T-34 tripeptide. The trade name is not on that record. Chonluten is not a PubChem synonym.
That T-34 in PMID 22803148 is proven identical to marketplace Chonluten
The opened abstract does not print that link. Label: NOT Chonluten efficacy.
That research-vial material is chemically identical to the 100 ng/mL culture reagent in Avolio 2022
SRP pages do not print sequence, CAS, salt, or a public COA.
A research-use dose, reconstitution scheme, or equivalent to any oral cytogen capsule
Out of scope for this facts page. No human dosing protocol appears here.
Safety of laboratory or any other use in humans or animals
No opened toxicology program, no opened SAE table.
Marketing claims vs opened evidence
Category names are store taxonomy, not clinical indications. Keep the sparse/limited evidence wording. Do not invent a sequence as if SRP verified it.
| Claim type | What opened pages actually support | Flag |
|---|---|---|
| SRP 20 mg page: name Chonluten 20 mg Research Peptide Vial; 20 mg; categories Peptide Bioregulators / Respiratory Research; For laboratory research only. Not for human or animal use… | Quote-accurate for that URL. http://simpleresearchpeptides.com/product/chonluten-20-mg/ | Category names are store taxonomy, not clinical indications. |
| SRP page: verify sequence, salt form, and assay | Quote-accurate. Consistent with the identity gap (no sequence printed). | Do not invent a sequence as if SRP verified it. |
| SRP index: Sparse/limited evidence; English-language, independently replicated evidence base is limited. | Matches what this research pass found. | Keep that wording. Evidence is sparse. |
| Sequence is Glu-Asp-Gly / EDG. | Printed in Avolio 2022 Methods and in two Khavinson reviews. | Fair if attributed to those papers, not to the SRP vial. |
| CAS 75007-24-8. | Printed on PubChem CID 194641 for glutamyl-aspartyl-glycine. | Do not present it as an SRP-printed CAS. PubChem does not call the CID Chonluten. |
| FDA approved / treats COPD / asthma / COVID. | Contradicted by openFDA empty results, ClinicalTrials.gov zero studies, and the fact that the COVID paper is a review of prospects. | Do not use. |
| Using Bronchogen rat-COPD or ADEL bronchial-gene papers as Chonluten proof. | Opened pages print different sequences (ADEL / AEDL tetrapeptide vs EDG tripeptide). | Common catalog error. NOT Chonluten efficacy. |
| Honluten is the same thing. | Not printed on any opened primary paper or Europe PMC record (0 hits). | Do not use until a primary page prints it. |
Research-only caution
Chonluten is a laboratory research peptide. It is not an FDA-approved drug for human use. This page is educational. It does not provide dosing, reconstitution, administration, or any human-use instructions.
Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application.
Laboratory identity is the first practical issue. Opened papers print Chonluten as Glu-Asp-Gly (EDG). PubChem CID 194641 is glutamyl-aspartyl-glycine / T-34 tripeptide, CAS 75007-24-8. Chonluten is not a PubChem synonym. SRP product pages do not print sequence, CAS, UNII, or formula. A method written for Bronchogen (ADEL or AEDL), Epitalon (AEDG), or any other bioregulator is not automatically valid for this tripeptide.
Biological inference has the same problem. Avolio 2022 is one THP-1 cell paper. Two reviews name EDG. 2020 review oral COPD / COVID sentences are unverified review claims. Human trials: NONE. Independently sourced research peptides are not established as equivalent to the 100 ng/mL culture reagent in Avolio 2022. Confirm sequence and assay before treating a vial as the literature compound.
Common questions
What is Chonluten in one sentence?
A Khavinson-catalog synthetic tripeptide printed as Glu-Asp-Gly (EDG) in the opened papers above, sold as a 20 mg research vial. Research-use-only. Evidence is sparse.
Is the sequence really EDG?
Yes, on three opened papers that print the trade name next to Glu-Asp-Gly / EDG (Avolio 2022 Methods, PMID 35408963; Khavinson 2020, PMID 32987757; Khavinson 2022 Table 2, PMID 35887081). SRP’s own page does not print it. Confirm the vial by sequence and assay.
Is it the same as T-34?
PubChem lists T-34 tripeptide as a synonym of Glu-Asp-Gly (CID 194641). The opened 2012 T-34 abstract (PMID 22803148) does not print Chonluten. Treat T-34 as a possible laboratory code for the same tripeptide, not as a second confirmed clinical article. Label: NOT Chonluten efficacy.
How is it different from Bronchogen?
Bronchogen is a tetrapeptide (printed as ADEL or AEDL, depending on the paper). Chonluten is a tripeptide (EDG). Several opened lung-remodeling and bronchial-gene papers test Bronchogen / ADEL, not Chonluten. The ADEL vs AEDL inconsistency is recorded and is not collapsed. Do not merge the two molecules.
How is it different from Epitalon, Livagen, Ovagen, or Vesugen?
Different sequences on the opened Avolio Methods and 2022 transport table: Epitalon AEDG; Livagen KEDA; Ovagen EDL; Vesugen KED. Shared bioregulator branding is not shared pharmacology.
Did any human trial test Chonluten?
No opened trial. ClinicalTrials.gov returned zero studies. A 2020 review from the same institute asserts oral EDG use in bronchopulmonary disease; those sentences are not an opened RCT. Human trials: NONE. Do not invent a trial registration number.
Is it FDA-approved?
Not on any opened FDA, NCATS, or openFDA page as of 16 August 2026. Not FDA-approved.
Can SRP vials be used as a human dose substitute?
No. SRP listings are for laboratory research only and are not for human or animal use. This page does not provide reconstitution, administration, or dosing instructions. Not medical advice. Not for human use.
Is the evidence mixed or just thin?
Thin. Sparse. One opened primary cell-culture paper names and tests Chonluten (Avolio 2022 THP-1). Two opened reviews name it. The rest of the respiratory-looking literature that this pass opened is Bronchogen / ADEL. Independent English-language replication, PK, and controlled human data are not established.
Does this page include human dosing?
No. There is no human dosing, reconstitution, or administration protocol on this page. Research use only.
Citations used on this page
Sources actually opened for this draft. PMIDs that name Chonluten / EDG: 35408963, 32987757, 35887081. Distinction-only PMIDs (label as NOT Chonluten efficacy): 22803148, 25015171, 21240358, 22808515, 26468022, 30199201, 34834147. No trial registration number is listed because ClinicalTrials.gov returned 0 studies. Do not invent one.
- Avolio F, Martinotti S, Khavinson VK, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022;23(7):3607. PMID 35408963. DOI 10.3390/ijms23073607. PMC8999041. Primary experiment that names and tests Chonluten.
- Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules. 2020;25(19):4389. PMID 32987757. DOI 10.3390/molecules25194389. PMC7583759. Review; names EDG = Chonluten. Oral COPD / COVID = unverified review claims.
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022;23(14):7733. PMID 35887081. DOI 10.3390/ijms23147733. PMC9323678. Review + docking; Table 2 prints Chonluten (EDG). LAT1 docking only.
- Khavinson VKh, Lin’kova NS, Dudkov AV, Polyakova VO, Kvetnoi IM. Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins. Bull Exp Biol Med. 2012;152(5):615-618. PMID 22803148. DOI 10.1007/s10517-012-1590-2. Abstract only; T-34 / gastric ulcer; cited by #2 for EDG gene claims. NOT Chonluten efficacy.
- Khavinson VKh, Tendler SM, Vanyushin BF, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791. PMID 25015171. DOI 10.1007/s00408-014-9620-7. ADEL, not Chonluten — distinction only. NOT Chonluten efficacy.
- Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, et al. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011;150(3):375-377. PMID 21240358. DOI 10.1007/s10517-011-1146-x. Bronchogen ADEL — distinction only. NOT Chonluten efficacy.
- Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-151. PMID 22808515. DOI 10.1007/s10517-012-1664-1. Bronchogen printed as Ala-Glu-Asp-Leu (AEDL) — distinction only. NOT Chonluten efficacy.
- Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, et al. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med. 2015;159(5):685-688. PMID 26468022. DOI 10.1007/s10517-015-3047-x. Tetrapeptide Bronchogen rat COPD — distinction only. NOT Chonluten efficacy.
- Titova et al. 2017. PMID 30199201. Russian title; no DOI on the opened Europe PMC record. Abstract: tetrapeptide bronchogen in a COPD model. NOT Chonluten efficacy.
- Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID 34834147. DOI 10.3390/molecules26227053. PMC8619776. Class review; does not name Chonluten. NOT Chonluten efficacy.
- PubChem CID 194641 (glutamyl-aspartyl-glycine / Glu-Asp-Gly / T-34 tripeptide; CAS 75007-24-8). https://pubchem.ncbi.nlm.nih.gov/compound/194641 and PUG REST/PUG View (opened 16 August 2026). Chonluten is not a PubChem synonym.
- ClinicalTrials.gov API v2 query chonluten / honluten / Glu-Asp-Gly — 0 studies (opened 16 August 2026). No trial registration number to list.
- NCATS Inxight substances search chonluten — 0 records (opened 16 August 2026).
- openFDA Drugs@FDA and label APIs — no matches for chonluten (opened 16 August 2026).
- IUPHAR/BPS ligand search API — no ligands for chonluten or Glu-Asp-Gly (opened 16 August 2026).
- Simple Research Peptides. Chonluten 20 mg product page (opened 16 August 2026): http://simpleresearchpeptides.com/product/chonluten-20-mg/. Title: Chonluten 20 mg Research Peptide Vial. Sequence, CAS, UNII, molecular formula, and a public COA were not printed on the fetched page. For laboratory research only. Not for human or animal use.
- Simple Research Peptides. Compound Research Guides directory (opened 16 August 2026): http://simpleresearchpeptides.com/research-compound-directory/compound-research-guides/. Listing: Chonluten 20 mg under Longevity; evidence tag Sparse/limited evidence.
Allowed PMID list used on this page. Named Chonluten / EDG: 35408963, 32987757, 35887081. Distinction / T-34 abstract / class review — do not cite as Chonluten efficacy: 22803148, 25015171, 21240358, 22808515, 26468022, 30199201, 34834147. Allowed DOI list: 10.3390/ijms23073607; 10.3390/molecules25194389; 10.3390/ijms23147733; 10.1007/s10517-012-1590-2; 10.1007/s00408-014-9620-7; 10.1007/s10517-011-1146-x; 10.1007/s10517-012-1664-1; 10.1007/s10517-015-3047-x; 10.3390/molecules26227053. Opened PMC: PMC8999041, PMC7583759, PMC9323678, PMC8619776. No other PMIDs were added. No trial registration number was invented.
Educational information only. Chonluten is a synthetic tripeptide printed as Glu-Asp-Gly (EDG) in opened papers. It is not Bronchogen, not Epitalon, and not an FDA-approved drug. Evidence is sparse: one primary cell paper (Avolio 2022 THP-1). Human trials: NONE. 2020 review oral COPD / COVID = unverified review claims. PubChem CID 194641 / CAS 75007-24-8 is Glu-Asp-Gly / T-34; Chonluten is not a PubChem synonym. Laboratory research use only; not for human or animal use. Not medical advice. Not for human use. No human dosing protocol. Last source review: 16 August 2026 (America/Indianapolis). Locked draft converted to HTML the same day. For laboratory research only. Not for human or veterinary use.